ToolGen successful with CRISPR/Cas9 European patent

ToolGen, Inc. has announced that on July 26, 2018 the European Patent Office issued a decision to grant to ToolGen a European patent. This covers the CRISPR-Cas9 genome editing system adapted for mammalian cells.

ToolGen, Inc. is a biotechnology company focused on the development and application of genome editing technologies and the CRISPR-Cas9 system is a cutting-edge tool used for genome editing in human cells, as well as animals and plants.

Widely used in biomedical research and biotechnology, CRISPR/Cas9 technology enables targeted genetic modifications in cells and whole organisms, which can lead to development of novel therapies and value-added crops and livestock.

CRISPR technology is used to modify genomes.

Jongmoon Kim, the Chief Executive Officer of ToolGen said: “We are committed to developing transformative therapeutics and agricultural products using our CRISPR-Cas9 genome editing system.

“This patent grant from the EPO begins to lay the groundwork for our intellectual property in Europe and further validates our research efforts.

“With this patent in hand, we intend to pursue additional IP applications and licensing partnerships worldwide.”

The European patent (number EP 2912175 B1) that was granted is entitled “Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas Protein-encoding nucleic acid or Cas protein, and use thereof,” and lists ToolGen, Inc. as the applicant.

Twitter has reacted to the ToolGen news.

In addition to Europe, ToolGen is pursuing patent rights worldwide and has issued patents in South Korea and Australia. ToolGen has licensing partners for these patent rights in agriculture and clinical research.

They have one of the earliest filing dates for the use of CRISPR/Cas9 in mammalian systems, which is significant in first-to-file patent systems such as that of the EPO.

How the CRISPR/Cas9 genome editor works

ToolGen’s European patent is based on a patent application filed by ToolGen on October 23, 2012, and would cover key European countries including Austria, Denmark, France, Germany, Italy, Netherlands, Spain, Sweden, and United Kingdom.

The European patent can be opposed by interested parties within nine months of the publication of the decision to grant.

It creates and holds intellectual property rights for essential tools and technologies including CRISPR/Cas9, for editing the genetic information in microbial, plant, animal, and human cells.

ToolGen’s mission is to translate the potential of its innovative platform technology into transformative products for biomedicine and agriculture.

You Might Also Like